Literature DB >> 12704149

Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection.

Silvia B Boscardin1, Sheila S Kinoshita, Adriana E Fujimura, Mauricio M Rodrigues.   

Abstract

Immunization of mice with plasmids containing Trypanosoma cruzi genes induced specific antibodies, CD4(+) Th1 and CD8(+) Tc1 cells, and protective immunity against infection. In most cases, plasmids used for DNA vaccination contained genes encoding antigens expressed by trypomastigotes, the nonreplicative forms of the parasite. In this study, we explored the possibility of using genes expressed by amastigotes, the form of the parasite which replicates inside host cells, for experimental DNA vaccination. For that purpose, we selected a gene related to the amastigote surface protein 2 (ASP-2), an antigen recognized by antibodies and T cells from infected mice and humans, for our study. Using primers specific for the asp-2 gene, four distinct groups of genes were amplified from cDNA from amastigotes of the Y strain of T. cruzi. At the nucleotide level, they shared 82.3 to 89.9% identity with the previously described asp-2 gene. A gene named clone 9 presented the highest degree of identity with the asp-2 gene and was selected for immunological studies. Polyclonal antisera raised against the C terminus of the recombinant protein expressed by the clone 9 gene reacted with an antigen of approximately 83 kDa expressed in amastigotes of T. cruzi. Immunization of BALB/c mice with eukaryotic expression plasmids containing the clone 9 gene elicited specific antibodies and CD4(+) T-cell-dependent gamma interferon secretion. Upon challenge with trypomastigotes, mice immunized with plasmids harboring the clone 9 gene displayed reduced parasitemia and survived lethal infection. We concluded that amastigote cDNA is an interesting source of antigens that can be used for immunological studies, as well as for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704149      PMCID: PMC153249          DOI: 10.1128/IAI.71.5.2744-2757.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

1.  Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection.

Authors:  V Michailowsky; N M Silva; C D Rocha; L Q Vieira; J Lannes-Vieira; R T Gazzinelli
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Infection by Trypanosoma cruzi. Identification of a parasite ligand and its host cell receptor.

Authors:  M H Magdesian; R Giordano; H Ulrich; M A Juliano; L Juliano; R I Schumacher; W Colli; M J Alves
Journal:  J Biol Chem       Date:  2001-03-07       Impact factor: 5.157

3.  Molecular cloning of the gene encoding the 83 kDa amastigote surface protein and its identification as a member of the Trypanosoma cruzi sialidase superfamily.

Authors:  H P Low; R L Tarleton
Journal:  Mol Biochem Parasitol       Date:  1997-09       Impact factor: 1.759

4.  Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.

Authors:  B Wizel; N Garg; R L Tarleton
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

5.  Expression and evolution of members of the Trypanosoma cruzi trypomastigote surface antigen multigene family.

Authors:  B J Ruef; B D Dawson; D Tewari; D L Fouts; J E Manning
Journal:  Mol Biochem Parasitol       Date:  1994-01       Impact factor: 1.759

6.  Amastigote and epimastigote stage-specific components of Trypanosoma cruzi characterized by using monoclonal antibodies. Purification and molecular characterization of an 83-kilodalton amastigote protein.

Authors:  A A Pan; D McMahon-Pratt
Journal:  J Immunol       Date:  1989-08-01       Impact factor: 5.422

7.  Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.

Authors:  M M Rodrigues; M Ribeirão; V Pereira-Chioccola; L Renia; F Costa
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

8.  Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Authors:  Nisha Garg; Rick L Tarleton
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro.

Authors:  G N Vespa; F Q Cunha; J S Silva
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

10.  Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex.

Authors:  M Corr; L F Boyd; S R Frankel; S Kozlowski; E A Padlan; D H Margulies
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  26 in total

1.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice.

Authors:  Fanny Tzelepis; Bruna C G de Alencar; Marcus L O Penido; Ricardo T Gazzinelli; Pedro M Persechini; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

3.  Adenovirus vector-induced CD8⁺ T effector memory cell differentiation and recirculation, but not proliferation, are important for protective immunity against experimental Trypanosoma cruzi Infection.

Authors:  José Ronnie Vasconcelos; Mariana R Dominguez; Ramon L Neves; Jonatan Ersching; Adriano Araújo; Luara I Santos; Fernando S Virgilio; Alexandre V Machado; Oscar Bruna-Romero; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Hum Gene Ther       Date:  2014-03-31       Impact factor: 5.695

4.  Characterization and Diagnostic Application of Trypanosoma cruzi Trypomastigote Excreted-Secreted Antigens Shed in Extracellular Vesicles Released from Infected Mammalian Cells.

Authors:  Norma L Bautista-López; Momar Ndao; Fabio Vasquez Camargo; Takeshi Nara; Takeshi Annoura; Darryl B Hardie; Christoph H Borchers; Armando Jardim
Journal:  J Clin Microbiol       Date:  2016-12-14       Impact factor: 5.948

5.  Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.

Authors:  Paula Ordonhez Rigato; Bruna C de Alencar; José Ronnie C de Vasconcelos; Mariana R Dominguez; Adriano F Araújo; Alexandre V Machado; Ricardo T Gazzinelli; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

6.  Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.

Authors:  Eduardo L V Silveira; Carla Claser; Filipe A B Haolla; Luiz G Zanella; Mauricio M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

7.  Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.

Authors:  Bruna C G de Alencar; Pedro M Persechini; Filipe A Haolla; Gabriel de Oliveira; Jaline C Silverio; Joseli Lannes-Vieira; Alexandre V Machado; Ricardo T Gazzinelli; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

8.  Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.

Authors:  G Salay; M L Dorta; N M Santos; R A Mortara; C Brodskyn; C I Oliveira; C L Barbiéri; M M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2007-07-11

9.  Genetic immunization converts the trypanosoma cruzi B-Cell mitogen proline racemase to an effective immunogen.

Authors:  Marianne A Bryan; Karen A Norris
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

10.  Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast.

Authors:  Elaine C Vicentin; Kátia S Françoso; Mariana V Rocha; Dmitri Iourtov; Fernanda L Dos Santos; Flávia S Kubrusly; Maria A Sakauchi; Isaias Raw; Francois Nosten; Laurent Rénia; Mauricio M Rodrigues; Bruce Russell; Irene S Soares
Journal:  Infect Immun       Date:  2013-12-30       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.